Advances in rheumatoid arthritis

No Thumbnail Available
File version
Author(s)
Jones, Graeme
Nash, Peter
Hall, Stephen
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2017
Size
File type(s)
Location
License
Abstract

There are now eight approved biological disease-modifying antirheumatic drugs (bDMARDs), two biosimilars and one targeted synthetic DMARD in Australia with a number of new products and biosimilars in the pipeline. bDMARDs have excellent efficacy, especially when combined with traditional DMARDs, and a well characterised but manageable safety profile. These expanded therapeutic options have revolutionised patient care and made remission (including drug free remission) a realistic goal. Evidence of a "window of opportunity" that changes the long term phenotype of the disease has been well established, so therapy should be commenced as early as possible in the disease process and a shared care model between general practitioner and rheumatologist provides the best outcomes. While there is no cure for rheumatoid arthritis, treatment has improved to the point where many patients can achieve a normal quality of life.

Journal Title
Medical Journal of Australia
Conference Title
Book Title
Edition
Volume
206
Issue
5
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Biomedical and clinical sciences
Clinical sciences
Immunology
Psychology
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
SERIOUS INFECTION
Persistent link to this record
Citation
Jones, G; Nash, P; Hall, S, Advances in rheumatoid arthritis, Medical Journal of Australia, 2017, 206 (5), pp. 221-224
Collections